Unicycive Therapeutics (UNCY) CFO awarded 169,500 RSUs as stock compensation
Rhea-AI Filing Summary
Townsend John reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics CFO John Townsend received a grant of 169,500 restricted stock units (RSUs) tied to the company’s common stock. This is a stock-based compensation award, not an open-market share purchase or sale.
According to the footnote, 23,542 shares vest upon grant, and an additional 4,708 shares vest over 31 months beginning on June 1, 2026, as long as he continues to serve at the company. Following this award, Townsend is shown as directly holding 169,500 RSUs, aligning his compensation more closely with the company’s future stock performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Townsend John
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 169,500 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 169,500 shares (Direct)
Footnotes (1)
- F1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
Key Figures
RSU grant size: 169,500 RSUs
Immediate vesting portion: 23,542 shares
Monthly vesting tranche: 4,708 shares
+2 more
5 metrics
RSU grant size
169,500 RSUs
Restricted Stock Unit award to CFO John Townsend
Immediate vesting portion
23,542 shares
Shares vest upon grant under RSU Award
Monthly vesting tranche
4,708 shares
Vests over 31 months beginning June 1, 2026
Total RSUs after transaction
169,500 units
Total restricted stock units following the grant
Transaction date
May 14, 2026
Date of RSU grant to CFO
Key Terms
Restricted Stock Unit, RSU Award, vest, common stock
4 terms
Restricted Stock Unit financial
"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSU Award financial
"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"
vest financial
"23,542 shares vest upon grant and 4,708 shares vest over 31 months"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
common stock financial
"payable solely in common stock of the Issuer"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Unicycive Therapeutics (UNCY) CFO John Townsend receive in this Form 4/A?
The CFO received a grant of 169,500 restricted stock units (RSUs) tied to Unicycive Therapeutics common stock. This represents stock-based compensation rather than an open-market transaction, aligning part of his pay with future share performance.
How many Unicycive (UNCY) RSUs vest immediately for the CFO?
The filing states that 23,542 shares vest upon grant from the CFO’s RSU award. Immediate vesting gives him an initial stake right away, while the remaining units follow a longer vesting schedule tied to continued service with the company.
What is the vesting schedule for the remaining Unicycive (UNCY) RSUs?
The footnote explains that 4,708 shares vest over 31 months starting June 1, 2026. These vesting conditions require the CFO to maintain continued service with Unicycive Therapeutics for the shares to be delivered over time.
Is the Unicycive (UNCY) CFO Form 4/A an open-market stock purchase or sale?
No, the transaction is a grant of restricted stock units, not an open-market buy or sell. The Form 4/A records compensation-related equity awarded to the CFO, which will convert into common shares as the vesting conditions are met.
How many Unicycive (UNCY) RSUs does the CFO hold after this award?
After the grant, total RSUs following the transaction are reported as 169,500 units. These RSUs represent a right to receive common stock in the future, subject to the specified vesting terms and continued employment with Unicycive Therapeutics.